Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

WuXi AppTec Passed Client Data to China Officials, Reuters Says

publication date: Mar 29, 2024

WuXi AppTec, the China based CRDMO, continues to face charges that it steals information from its biopharma clients, sharing it with China’s government. According to a Reuters report, US intelligence officials told members of the US Senate in late February that WuXi has illegally transferred intellectual property from US clients to China authorities. The senators are writing a proposed law that sanctions WuXi and could close the company’s US operations. WuXi AppTec denied the charges, saying that protecting client’s data is “of utmost importance” to it, that it has never been accused of misusing information, and that it complies with all US laws. Currently, WuXi derives 65% of its revenues from US companies. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital